Federal Budget: What it means for the CSL (ASX:CSL) share price

The Federal Budget has earmarked lots of cash for COVID-19 treatments. Here's why that's good news for the CSL Limited (ASX: CSL) share price.

| More on:
CSL share price represented by hand in blue glove picks out a vial labelled 'covid-19 vaccine' from a row of vials

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has done well in 2020 and the Federal Budget could have more good news in store.

While the S&P/ASX 200 Index (ASX: XJO) has slumped 10.9% this year, the CSL share price has climbed 4.4% higher.

I think the Federal Budget contained good news for vaccines and those organisations involved with the push towards coronavirus treatments. This to me says the CSL share price could be on the move in the coming months.

What the Federal Budget means for the CSL share price

There were a lot of areas covered by Treasurer Josh Frydenberg in last night's Federal Budget. One of those surrounded potential COVID-19 vaccine candidates such as that being developed by the University of Queensland 

CSL is partnering with the Aussie university as it researches a potential vaccination candidate. That's already seen the Aussie biotech ink a deal with the government to supply 84.8 million doses of any COVID-19 vaccine.

However, Treasurer Frydenberg has earmarked billions of dollars for spending on COVID-19 vaccines, both here and abroad. $1.7 billion is already being spent in agreements for the University of Oxford and the University of Queensland vaccines.

There's also more money going towards the CSIRO and the Medical Research Future Fund for more COVID-19 research.

I see more focus on healthcare and vaccine development as good news for the CSL share price. The more government support and goodwill towards the sector that exists, the better the operating environment for CSL.

Depending on the successful vaccine candidate(s), we could also see further deals signed with CSL depending on global and domestic demand.

Foolish takeaway

The CSL share price has already outperformed in 2020 but I think it has further to run. I think COVID-19 will continue to dominate share market movements in the next 6-12 months.

That means major partners like CSL may continue to hold their gains despite volatility in the market.

Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Ozempic maker Novo Nordisk plunges 22%. What could this mean for Resmed shares?

Novo Nordisk just lost $100 billion in market value.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 11% today

Let's see why investors are bidding this stock higher on Wednesday.

Read more »

stockmarket graphic in background with man looking at stockmarket on phone
Healthcare Shares

CSL shares are a buy – UBS

This expert is optimistic on what the business can achieve despite headwinds.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »